Patents by Inventor Haijuan Gu

Haijuan Gu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PD-L1 antibody and IL-7 fusions
    Patent number: 11401331
    Abstract: Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 2, 2022
    Assignee: I-Mab Biopharma US Limited
    Inventors: Lei Fang, Feifei Cui, Haijuan Gu, Zhengyi Wang, Bingshi Guo, Jingwu Zang
  • ANTI-CXCL13 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES AND CANCER
    Publication number: 20210284724
    Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 16, 2021
    Inventors: Haijuan Gu, Qiumei Yang
  • Anti-CXCL13 antibodies
    Patent number: 11028164
    Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: June 8, 2021
    Assignee: I-Mab Biopharma US Limited
    Inventors: Haijuan Gu, Qiumei Yang
  • ANTI-CXCL13 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES AND CANCER
    Publication number: 20200399360
    Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
    Type: Application
    Filed: September 18, 2019
    Publication date: December 24, 2020
    Inventors: Haijuan Gu, Qiumei Yang
  • ANTI-PD-L1 ANTIBODY AND IL-7 FUSIONS
    Publication number: 20190352405
    Abstract: Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.
    Type: Application
    Filed: January 25, 2019
    Publication date: November 21, 2019
    Inventors: Lei Fang, Feifei Cui, Haijuan Gu, Zhengyi Wang, Bingshi Guo